Chopra Ian, Schofield Christopher, Everett Martin, O'Neill Alex, Miller Keith, Wilcox Mark, Frère Jean-Marie, Dawson Mike, Czaplewski Lloyd, Urleb Uros, Courvalin Patrice
Antimicrobial Research Centre and Research Institute of Molecular and Cellular Biology, University of Leeds, Leeds, UK.
Lancet Infect Dis. 2008 Feb;8(2):133-9. doi: 10.1016/S1473-3099(08)70018-5.
This consensus statement presents the conclusions of a group of academic and industrial experts who met in London in September, 2006, to consider the issues associated with the treatment of hospital infections caused by Gram-negative bacteria. The group discussed the severe clinical problems arising from the emergence of antibiotic resistance in these bacteria and the lack of new antibacterial agents to challenge the threat. The discovery of new drugs active against hospital-acquired Gram-negative bacteria is essential to prevent a future medical and social catastrophe. An important strategy to promote drug discovery will be the development of focused cooperations between academic institutions and small pharmaceutical companies.
本共识声明展示了一组学术和行业专家于2006年9月在伦敦会面后得出的结论，他们会面的目的是审议与革兰氏阴性菌引起的医院感染治疗相关的问题。该小组讨论了这些细菌中抗生素耐药性出现所引发的严重临床问题，以及缺乏新的抗菌药物来应对这一威胁的情况。发现对医院获得性革兰氏阴性菌有效的新药对于预防未来的医学和社会灾难至关重要。促进药物研发的一项重要策略将是学术机构与小型制药公司之间开展有针对性的合作。
